Frequency Therapeutics, Inc. (FREQ)
Frequency Therapeutics, Inc., a clinical-stage biotechnology company, focuses on harnessing the body's innate biology to repair or reverse damage caused by a range of degenerative diseases.
Its Progenitor Cell Activation approach, uses combinations of small molecules to activate progenitor cells within the body to create functional tissue.
The company's lead product candidate is FX-322, which is in Phase IIa clinical trial to treat the underlying cause of sensorineural hearing loss. It is also developing medicines for patients across a range of degenerative conditions, including multiple sclerosis, and diseases of the muscle, gastrointestinal tract, skin, and bone.
Frequency Therapeutics, Inc. has a licencse and collaboration agreement with Astellas Pharma Inc. for the development and commercialization of FX-322, as well as collaboration and licensing agreements with Massachusetts Eye and Ear, Mass General Brigham, the Massachusetts Institute of Technology, The Scripps Research Institute, and Cambridge Enterprises Limited.
The company was incorporated in 2014 and is headquartered in Lexington, Massachusetts.
|IPO Date||Oct 3, 2019|
75 Hayden Avenue
Lexington, MA 02421
|Phone||781 315 4600|
|Fiscal Year||January - December|
|Reporting Currency||US Dollars|
|David L. Lucchino||Co-Founder, President, Chief Executive Officer and Director|
|Peter P. Pfreundschuh||Chief Financial Officer|
|Wendy S. Arnold||Chief People Officer|
|Dr. Christopher R. Loose||Co-Founder and Chief Scientific Officer|
|William J. McLean Ph.D.||Co-founder and Senior Vice President of Hearing Biology and Translational Research|
|Richard J. Mitrano||Vice President of Finance and Operations|
|Dr. Jeff Hrkach||Senior Vice President of Technology Development|
|Dr. Dana C. Hilt||Chief Medical Officer|
|Dr. Carl P. LeBel||Chief Development Officer|
|Dr. William W. Chin M.D.||Senior Vice President of Translational Medicine|
Latest SEC Filings
|Dec 21, 2021||4||Statement of changes in beneficial ownership of securities|
|Dec 10, 2021||8-K||Current report|
|Dec 10, 2021||424B5||Prospectus [Rule 424(b)(5)]|
|Dec 9, 2021||8-K||Current report|
|Nov 15, 2021||10-Q||Quarterly report [Sections 13 or 15(d)]|
|Nov 15, 2021||8-K||Current report|
|Nov 9, 2021||8-K||Current report|
|Nov 4, 2021||4||Statement of changes in beneficial ownership of securities|
|Oct 21, 2021||8-K||Current report|
|Oct 7, 2021||4||Statement of changes in beneficial ownership of securities|
|View All SEC Filings|